Close

Inverness Medical launches new FDA cleared C. DIFF QUIK CHEK COMPLETE rapid test

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Ethical Collaboration in Healthcare: New Principles Adopted

Leading healthcare organizations unite to develop a code of...

CMS in US Launches WISeR Model to Enhance Original Medicare

The Centers for Medicare & Medicaid Services (CMS) is...

England GP IT Market Witnesses Shake-Up Unseen in 25 Years

England’s National Health Service, which is popularly known as...

Label Expansion In Alzheimers Gives GE HealthCare An Edge

The US Food and Drug Administration (FDA) has gone...

Inverness Medical Innovations, Inc., a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health management, announced that it will begin marketing and distributing the new C. DIFF QUIK CHEK COMPLETE™ rapid test as an in vitro diagnostic aid for Clostridium difficile associated disease (CDAD). This follows TECHLAB®, Inc.’s recent clearance from the FDA to manufacture the product for Inverness.

The C. DIFF QUIK CHEK COMPLETE™ test offered by Inverness Medical is the only device that simultaneously detects both C. difficile glutamate dehydrogenase (GDH) and C. difficile toxins A and B in one simple assay. It can be used for screening while also confirming the presence of toxigenic C. difficile strains. The test provides results in less than 30 minutes from fecal samples, enabling rapid diagnosis and initiation of appropriate patient management. With use of a C. difficile rapid test, patients can be effectively isolated at an earlier stage of illness, reducing the risk of cross contamination and widespread outbreaks.

The C. difficile antigen glutamate dehydrogenase (GDH) used in the test is common to all strains of C. difficile and has been identified as an excellent screening marker for the infection. The new C. DIFF QUIK CHEK COMPLETE™ test, developed and manufactured by TECHLAB®, Inc. in Blacksburg, VA,  provides a more complete picture of the patient’s disease state within one single test format with quicker time to results and higher negative predictive value (less false negative results) when compared to alternative existing testing methods.

Latest stories

Related stories

Ethical Collaboration in Healthcare: New Principles Adopted

Leading healthcare organizations unite to develop a code of...

CMS in US Launches WISeR Model to Enhance Original Medicare

The Centers for Medicare & Medicaid Services (CMS) is...

England GP IT Market Witnesses Shake-Up Unseen in 25 Years

England’s National Health Service, which is popularly known as...

Label Expansion In Alzheimers Gives GE HealthCare An Edge

The US Food and Drug Administration (FDA) has gone...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back